...Ablynx N.V. (Euronext:ABLX), a public company valued at €660 million ($690 million). The other is Ossianix Inc....

...biologics that are unmet needs, particularly in difficult targets in the central nervous system," said Ossianix...
...now part of Pfizer Inc. Unlike a traditional antibody, which comprises heavy and light chains, Ossianix's...
...Ossianix. In 2014, Lundbeck re-upped its partnership with a specific focus in two areas, and Ossianix...

...The companies partnered for two projects using Ossianix's single domain antibody platform based on shark variable...
...based on shark variable new antigen receptor (VNAR) technology. The first project will further develop Ossianix's...
...preclinical animal testing this year. The second project is to develop bispecific products comprised of Ossianix's...

...described VNARs. Next steps could include generating humanized shark VNARs against known disease targets. Separately, Ossianix Inc....

...Ossianix said it partnered with H. Lundbeck to discover therapeutics for CNS diseases. Ossianix raised an...
...committee with representatives from both companies will have oversight of products developed under the deal. Ossianix...
...and co-founder and managing director of venBio. Ossianix investors include BioAdvance and the ALS Association. Ossianix Inc....

...Pa.) said it partnered with H. Lundbeck A/S (CSE:LUN) to discover therapeutics for CNS diseases. Ossianix...
...also will have non-exclusive rights to negotiate a license on technologies arising from the deal. Ossianix...
...of Pfizer Inc. (NYSE:PFE). Goodman is Ossianix's chairman and co-founder and managing director of venBio. Ossianix...

...Zurich, Switzerland Business: Inflammation, Cancer, Autoimmune Appointed: Frank Walsh as executive chairman, currently CEO of Ossianix Inc. WIR...